CD74 and breast cancer: While invasive breast cancers typically rely on high CD74 to maximize MIF-driven EMT (22), our results raise the possibility that ERα+ tumors such as MCF7 cells achieve similar outcomes through WISP1-mediated MIF amplification (Figure 1A).